<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>1104</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15795253</PubmedId>
            <Abstract>Anti-rabies virus immunoglobulin combined with rabies vaccine protects humans from lethal rabies infections. For cost and safety reasons, replacement of the human or equine polyclonal immunoglobulin is advocated, and the use of rabies virus-specific monoclonal antibodies (MAbs) is recommended. We produced two previously described potent rabies virus-neutralizing human MAbs, CR57 and CRJB, in human PER.C6 cells. The two MAbs competed for binding to rabies virus glycoprotein. Using CR57 and a set of 15-mer overlapping peptides covering the glycoprotein ectodomain, a neutralization domain was identified between amino acids (aa) 218 and 240. The minimal binding region was identified as KLCGVL (aa 226 to 231), with key residues K-CGV- identified by alanine replacement scanning. The critical binding region of this novel nonconformational rabies virus epitope is highly conserved within rabies viruses of genotype 1. Subsequently, we generated six rabies virus variants escaping neutralization by CR57 and six variants escaping CRJB. The CR57 escape mutants were only partially covered by CRJB, and all CRJB-resistant variants completely escaped neutralization by CR57. Without exception, the CR57-resistant variants showed a mutation at key residues within the defined minimal binding region, while the CRJB escape viruses showed a single mutation distant from the CR57 epitope (N182D) combined with mutations in the CR57 epitope. The competition between CR57 and CRJB, the in vitro escape profile, and the apparent overlap between the recognized epitopes argues against including both CR57 and CRJB in a MAb cocktail aimed at replacing classical immunoglobulin preparations.</Abstract>
            <ArticleYear>2005</ArticleYear>
            <ArticlePages>4672-8</ArticlePages>
            <ArticleTitle>Novel rabies virus-neutralizing epitope recognized by human monoclonal antibody: fine mapping and escape mutant analysis.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Marissen</LastName>
                    <ForeName>Wilfred E</ForeName>
                </Author>
                <Author>
                    <LastName>Kramer</LastName>
                    <ForeName>R Arjen</ForeName>
                </Author>
                <Author>
                    <LastName>Rice</LastName>
                    <ForeName>Amy</ForeName>
                </Author>
                <Author>
                    <LastName>Weldon</LastName>
                    <ForeName>William C</ForeName>
                </Author>
                <Author>
                    <LastName>Niezgoda</LastName>
                    <ForeName>Michael</ForeName>
                </Author>
                <Author>
                    <LastName>Faber</LastName>
                    <ForeName>Milosz</ForeName>
                </Author>
                <Author>
                    <LastName>Slootstra</LastName>
                    <ForeName>Jerry W</ForeName>
                </Author>
                <Author>
                    <LastName>Meloen</LastName>
                    <ForeName>Rob H</ForeName>
                </Author>
                <Author>
                    <LastName>Clijsters-van der Horst</LastName>
                    <ForeName>Marieke</ForeName>
                </Author>
                <Author>
                    <LastName>Visser</LastName>
                    <ForeName>Therese J</ForeName>
                </Author>
                <Author>
                    <LastName>Jongeneelen</LastName>
                    <ForeName>Mandy</ForeName>
                </Author>
                <Author>
                    <LastName>Thijsse</LastName>
                    <ForeName>Sandra</ForeName>
                </Author>
                <Author>
                    <LastName>Throsby</LastName>
                    <ForeName>Mark</ForeName>
                </Author>
                <Author>
                    <LastName>de Kruif</LastName>
                    <ForeName>John</ForeName>
                </Author>
                <Author>
                    <LastName>Rupprecht</LastName>
                    <ForeName>Charles E</ForeName>
                </Author>
                <Author>
                    <LastName>Dietzschold</LastName>
                    <ForeName>Bernhard</ForeName>
                </Author>
                <Author>
                    <LastName>Goudsmit</LastName>
                    <ForeName>Jaap</ForeName>
                </Author>
                <Author>
                    <LastName>Bakker</LastName>
                    <ForeName>Alexander B H</ForeName>
                </Author>
            </Authors>
            <Affiliations>Crucell Holland BV, Archimedesweg 4, P.O. Box 20482301, CA Leiden, The Netherlands.</Affiliations>
            <ArticleChemicalList>Antibodies, Monoclonal;Immunoglobulin G</ArticleChemicalList>
            <ArticleMeshHeadingsList>Amino Acid Sequence; Animals; Antibodies, Monoclonal(immunology); Cell Line, Tumor; Conserved Sequence; Humans; Immunoglobulin G(immunology); Mice; Molecular Sequence Data; Neuroblastoma; Neutralization Tests; Rabies(immunology); Rabies virus(genetics; immunology); Sequence Alignment; Sequence Homology, Amino Acid</ArticleMeshHeadingsList>
            <Journal>
                <Volume>79</Volume>
                <Issue>8</Issue>
                <Title>Journal of virology</Title>
                <Issn>1098-5514</Issn>
                <MedlineTa>J Virol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>CR57 226-231</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>KLCGVL</LinearSequence>
                        <StartingPosition>245</StartingPosition>
                        <EndingPosition>250</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>AAA47204.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11292</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 5</LocationOfData>
                <EpitopeId>31772</EpitopeId>
                <ReferenceStartingPosition>226</ReferenceStartingPosition>
                <ReferenceEndingPosition>231</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Author provided Identifier</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>The epitope was deduced.</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1865038</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Child</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11297</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Rabivac&lt;sup&gt;TM&lt;/sup&gt; human diploid cell vaccine</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <DoseSchedule>3 doses.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The mAb was generated by fusing SHM-D33 cells with human B cells from donors vaccined with Rabivac&lt;sup&gt;TM&lt;/sup&gt; human diploid cell vaccine (virus strain Pitman Moore 1503-3M, Behringwerke, Mar-burg, FRG). The details of the immunization procedure were described in the cited references: Dietzschold B. et al. 1990. J Virol.64: 3087-3090.  [PMID: 2335829] and Champion JM, et al. 2000. J Immunol Methods. 235: 81-90. [PMID: 10675760]. The parent mAb57 (IgG2) was cloned into an IgG1 expression vector.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope was deduced by the binding between mAb CR57 and three overlapping 8-mer peptides (KLKLCGVL, LKLCGVLG, and KLCGVLGL) containing this epitope, as measured by pepscan-ELISA. Alanine replacement scan through peptide LKLCGVLG showed that residue K, as well as the central CGV triplet were key residues within the epitope for mAb CR57 recognition.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>CR57</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Fragment of Source Antigen</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LKLCGVLG</LinearSequence>
                                        <StartingPosition>244</StartingPosition>
                                        <EndingPosition>251</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAA47204.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11292</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Tables 2 and 3</LocationOfData>
                        <BCellId>15335</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Child</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11297</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Rabivac&lt;sup&gt;TM&lt;/sup&gt; human diploid cell vaccine</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <DoseSchedule>3 doses.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The mAb was generated by fusing SHM-D33 cells with human B cells from donors vaccined with Rabivac&lt;sup&gt;TM&lt;/sup&gt; human diploid cell vaccine (virus strain Pitman Moore 1503-3M, Behringwerke, Mar-burg, FRG). The details of the immunization procedure were described in the cited references: Dietzschold B. et al. 1990. J Virol.64: 3087-3090.  [PMID: 2335829] and Champion JM, et al. 2000. J Immunol Methods. 235: 81-90. [PMID: 10675760]. The parent mAb57 (IgG2) was cloned into an IgG1 expression vector.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope specific mAb neutralized wild-type rabies virus CVS-11. Generation of mAb CR57 resisitant escape viruses confirmed that residues K1 and G4 of the epitope are critical for mAb recognition.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>CR57</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Rabies virus (strain CVS-11)</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Taxonomic Child</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>11294</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Rabies virus CVS-11 discontinuous epitope</EpitopeName>
                <EpitopeStructure>
                    <DiscontinuousRegionOnAccessionSequenceMolecule>
                        <ChemicalType>Discontinuous protein residues</ChemicalType>
                        <DiscontinuousResidues>N201, K245, G248, L250</DiscontinuousResidues>
                        <SourceMolecule>
                            <GenBankId>AAA47204.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11292</SourceOrganismId>
                    </DiscontinuousRegionOnAccessionSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 3 and results text page 4675</LocationOfData>
                <EpitopeId>153563</EpitopeId>
                <ReferenceRegion>N182, K226, G229, L231</ReferenceRegion>
                <EpitopeEvidenceCode>Author provided Identifier</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Partial Epitope</EpitopeStructureDefines>
                <EpitopeComments>The epitope was deduced.</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Tables 2 and 3</LocationOfData>
                        <BCellId>1864169</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Child</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11297</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Rabivac&lt;sup&gt;TM&lt;/sup&gt; human diploid cell vaccine</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <DoseSchedule>2 doses, administered at intervals of 14 days.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The mAb was generated by fusing SHM-D33 cells with human B cells from donors vaccined with Rabivac&lt;sup&gt;TM&lt;/sup&gt; human diploid cell vaccine (virus strain Pitman Moore 1503-3M, Behringwerke, Mar-burg, FRG). The details of the immunization procedure were described in the cited references: Dietzschold B. et al. 1990. J Virol.64: 3087-3090.  [PMID: 2335829] and Champion JM, et al. 2000. J Immunol Methods. 235: 81-90. [PMID: 10675760]. The parent mAbJB (IgG3) was cloned into an IgG1 expression vector.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope was deduced by generation of CRJB-resistant escape viruses and comparing the amino acid sequences of these viruses to wild type rabies virus CVS-11.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>CRJB</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Lambda</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Rabies virus (strain CVS-11)</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Taxonomic Child</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>11294</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

